Although some previous studies have established p90RSK as a potent therapeutic target in affecting cell migration and proliferation of cancer cells [11, 12], the combinatorial activity of cisplatin with RSK inhibition is not widely explored, especially in HNSCC. Here, RPS6KA3 is linked to cancer.